Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 9040 results

  1. Oesophageal cancer

    All NICE products on oesophageal cancer. Includes any guidance and quality standards.

    Topic page

  2. Stomach cancer

    All NICE products on stomach cancer. Includes any guidance and quality standards.

    Topic page

  3. Haematological cancers (QS150)

    This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (children, adults and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    1 June 2017
    View quality statements

    Sections for QS150

  4. Pregnancy

    All NICE products on pregnancy. Includes any guidance, advice and quality standards.

    Topic page

  5. Spinal conditions

    All NICE products on spinal conditions. Includes any guidance, advice and quality standards.

    Topic page

  6. Environment

    All NICE products on environment. Includes any guidance and quality standards.

    Topic page

  7. Immunisation

    All NICE products on immunisation. Includes any guidance and quality standards.

    Topic page

  8. Infectious disease prevention and control

    All NICE products on infectious disease prevention and control. Includes any guidance, advice and quality standards.

    Topic page

  9. Spasticity

    All NICE products on spasticity. Includes any guidance and advice.

    Topic page

  10. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 February 2019
    View quality statements

    Sections for QS180

  11. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  12. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  13. Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]

    In development Reference number: GID-TA11850 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  14. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    16 February 2023

    Sections for TA867

  15. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Technology appraisal guidance
    Published
    6 April 2023

    Sections for TA879